Medical Device Amendments of 1976

The Medical Device Amendments of 1976 is the foundational U.S. statute for medical device regulation — the legislative act that gave FDA the premarket authority over devices it still exercises today. Enacted as Public Law 94-295 and signed by President Gerald Ford on May 28, 1976, it amended the Federal Food, Drug, and Cosmetic Act (FD&C Act) by adding Section 513, creating the three-tier device classification system and the two core premarket pathways — 510(k) and PMA — that CASRAI’s FDA Medical Device Regulations guide covers in full operational detail. This entry focuses on the Amendments themselves: what prompted them, what they actually changed, and why the distinction between ‘device’ and ‘drug’ regulation traces back to this specific 1976 law rather than to the FD&C Act’s original 1938 text.

What prompted the Amendments

Before 1976, FDA had almost no premarket authority over medical devices. Drugs, by contrast, had been progressively re-regulated well before then, including by the Durham-Humphrey Amendment of 1951. The FD&C Act, passed in 1938 primarily in response to a drug-safety crisis, treated devices under the same general adulteration and misbranding provisions used for drugs — a standard that did nothing to require premarket evidence of safety or effectiveness for a device before it reached patients. That gap became a public and congressional concern through the 1960s and early 1970s as device-related injuries accumulated, and it came to a head with the Dalkon Shield, an intrauterine contraceptive device marketed without premarket safety review that was associated with serious injuries — including septic pregnancies, pelvic infections, and deaths — among the millions of women who used it. The Dalkon Shield controversy, alongside a broader congressional review (including the 1970 Cooper Committee study of device-related injuries commissioned by HEW), built the case that devices needed their own dedicated, risk-differentiated regulatory framework rather than a drug-shaped one. Congress passed the Medical Device Amendments in 1976 in direct response.

What the Amendments actually established

The Amendments added Section 513 to the FD&C Act and, with it, several structural pieces of device regulation that did not exist before:

• The three-tier classification system (Class I, II, III). For the first time, devices were sorted by risk level, with the degree of regulatory control — general controls, general plus special controls, or premarket approval — scaled to that risk. See CASRAI’s FDA Medical Device Regulations guide for how this system operates under its current implementing regulation, 21 CFR Part 860.
• Premarket notification — the 510(k) pathway. Named for its section number in the amended statute, this pathway let a new device reach market by demonstrating substantial equivalence to an already-legally-marketed predicate device, rather than independently proving safety and effectiveness from first principles.
• Premarket approval (PMA). The Amendments created PMA as the rigorous, data-intensive pathway reserved for Class III devices — those that sustain or support life, are implanted, or present unreasonable risk — where general and special controls alone were judged insufficient.
• The predicate-device / grandfathering mechanism. Devices already lawfully on the market when the law took effect were not forced through a retroactive safety review; they were classified based on their existing use, and their pre-1976 marketing history became the founding set of predicates that later 510(k) submitters could cite. This is why 510(k) review is a comparative substantial-equivalence exercise rather than an independent safety-and-effectiveness finding — the structure was built into the statute from the start, precisely to grandfather the existing device market in rather than force every device already in use through PMA-level review overnight.

Why the distinction matters today

The 1976 Amendments are the reason device regulation and drug regulation, though both administered by FDA under the same underlying FD&C Act, run on structurally different premarket logic. Drug approval under the FD&C Act (as later shaped by the Kefauver-Harris Amendments of 1962) generally requires independent proof of safety and effectiveness for every new drug. Device regulation under the 1976 Amendments instead lets most devices — the Class I and II majority — reach market via classification and, where required, substantial equivalence to something already marketed, reserving the drug-like independent-proof standard for Class III/PMA devices specifically. For research institutions and regulatory affairs offices working with investigational devices, understanding this history clarifies why the current framework (and the study-level Investigational Device Exemption process layered on top of it) is built the way it is — see CASRAI’s Investigational Device entry for how that IDE framework, adopted by FDA under authority the 1976 Amendments granted, governs device use in clinical research specifically.

Later amendments that built on this foundation

The 1976 Amendments were not the last word on device regulation — Congress and FDA have layered further changes on top of the same Section 513 framework in the decades since, including the Safe Medical Devices Act of 1990, the FDA Modernization Act of 1997, the Medical Device User Fee and Modernization Act (MDUFMA) of 2002 and its successor MDUFA reauthorizations, the Food and Drug Administration Safety and Innovation Act (FDASIA) of 2012 (which created the De Novo pathway as a formal statutory route), and the 21st Century Cures Act of 2016. Each refined timelines, fees, or added new pathways, but the core three-class structure and the 510(k)/PMA split established in 1976 remain the framework’s backbone.

For the current, operational version of this framework — how classification actually works, what a 510(k) submission requires, and how PMA and De Novo pathways function today — see CASRAI’s FDA Medical Device Regulations: Classification, 510(k), and PMA Pathways guide.